|
EP1400536A1
(en)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Method for making humanized antibodies
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
JP4213224B2
(ja)
|
1997-05-02 |
2009-01-21 |
ジェネンテック，インコーポレーテッド |
ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
|
|
AU2003270426A1
(en)
|
2002-09-12 |
2004-04-30 |
Avanir Pharmaceuticals |
PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
|
|
CN101928344B
(zh)
|
2002-10-17 |
2014-08-13 |
根马布股份公司 |
抗cd20的人单克隆抗体
|
|
WO2005103081A2
(en)
|
2004-04-20 |
2005-11-03 |
Genmab A/S |
Human monoclonal antibodies against cd20
|
|
EP3050963B1
(en)
|
2005-03-31 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
Process for production of polypeptide by regulation of assembly
|
|
AU2006301492B2
(en)
|
2005-10-11 |
2011-06-09 |
Amgen Research (Munich) Gmbh |
Compositions comprising cross-species-specific antibodies and uses thereof
|
|
US10155816B2
(en)
|
2005-11-28 |
2018-12-18 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
WO2008119353A1
(en)
|
2007-03-29 |
2008-10-09 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
RS53008B2
(sr)
|
2007-04-03 |
2022-12-30 |
Amgen Res Munich Gmbh |
Interspecijski specifičan cd3-epsilon vezujući domen
|
|
EP2155790A1
(en)
|
2007-05-31 |
2010-02-24 |
Genmab A/S |
Method for extending the half-life of exogenous or endogenous soluble molecules
|
|
ES2563027T3
(es)
|
2008-01-07 |
2016-03-10 |
Amgen Inc. |
Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática
|
|
CA2738568C
(en)
|
2008-10-01 |
2024-02-20 |
Micromet Ag |
Cross-species-specific single domain bispecific single chain antibody
|
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
|
UY32808A
(es)
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
|
CN102958942A
(zh)
|
2009-12-29 |
2013-03-06 |
新兴产品开发西雅图有限公司 |
异二聚体结合蛋白及其应用
|
|
TWI426920B
(zh)
|
2010-03-26 |
2014-02-21 |
Hoffmann La Roche |
雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
|
|
DK2560993T3
(da)
|
2010-04-20 |
2024-10-14 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
|
DK2714733T3
(da)
|
2011-05-21 |
2019-05-06 |
Macrogenics Inc |
Cd3-bindende molekyler, der er i stand til at binde til human og ikke-human cd3
|
|
MY169358A
(en)
|
2011-08-23 |
2019-03-26 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
US10344050B2
(en)
|
2011-10-27 |
2019-07-09 |
Genmab A/S |
Production of heterodimeric proteins
|
|
CA2864539C
(en)
|
2012-02-16 |
2022-06-07 |
Santarus, Inc. |
Antibody formulations
|
|
BR112015000167B1
(pt)
|
2012-07-06 |
2021-11-23 |
Genmab B.V. |
Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
|
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
|
CA2896359A1
(en)
|
2013-02-26 |
2014-09-04 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
|
CN105143270B
(zh)
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
MX373245B
(es)
|
2013-07-05 |
2020-05-11 |
Genmab As |
Anticuerpos cd3 humanizados o quiméricos.
|
|
JP2016531100A
(ja)
|
2013-07-12 |
2016-10-06 |
ザイムワークス，インコーポレイテッド |
二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
|
|
UA129760C2
(uk)
|
2013-12-17 |
2025-07-30 |
Дженентек, Інк. |
Анти-cd3 антитіло та спосіб його застосування
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
RS60739B1
(sr)
|
2014-11-17 |
2020-09-30 |
Regeneron Pharma |
Postupci za lečenje tumora upotrebom cd3xcd20 bispecifičnog antitela
|
|
CN107660214B
(zh)
|
2015-01-08 |
2022-02-08 |
根马布股份公司 |
针对cd3和cd20的双特异性抗体
|
|
US20160199399A1
(en)
|
2015-01-09 |
2016-07-14 |
Medical Prognosis Institute A/S |
Methods for predicting drug responsiveness in cancer patients
|
|
CN104922688A
(zh)
|
2015-02-10 |
2015-09-23 |
昆明贵研药业有限公司 |
奥沙利铂的环糊精复合物及制备方法
|
|
WO2017210485A1
(en)
|
2016-06-01 |
2017-12-07 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3 for use in the treatment of lymphoma
|
|
WO2018093821A1
(en)
*
|
2016-11-15 |
2018-05-24 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
MX389244B
(es)
|
2017-04-27 |
2025-03-20 |
Astrazeneca Ab |
Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer
|
|
BR112020015052A2
(pt)
|
2018-02-09 |
2020-12-08 |
Genmab A/S |
Composição farmacêutica, uso da composição farmacêutica, métodos para tratar câncer em um sujeito, para preparar uma composição farmacêutica e para preparar uma forma de dosagem unitária, forma de dosagem unitária, recipiente, e, kit-de-partes
|
|
PL3886875T3
(pl)
|
2018-11-30 |
2024-09-09 |
Juno Therapeutics, Inc. |
Metody leczenia z wykorzystaniem adoptywnej terapii komórkowej
|
|
MX2022001721A
(es)
*
|
2019-08-15 |
2022-03-11 |
Genmab As |
Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.
|
|
CA3176436A1
(en)
*
|
2020-05-08 |
2021-11-11 |
Tahamtan Ahmadi |
Bispecific antibodies against cd3 and cd20
|
|
AU2021342342A1
(en)
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibodies against CD3 and CD20 for treating chronic lymphocytic leukemia
|
|
EP4210742A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
CA3189883A1
(en)
|
2020-09-10 |
2022-03-17 |
Brian Elliott |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
MX2023002541A
(es)
|
2020-09-10 |
2023-03-14 |
Genmab As |
Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
|
|
IL301085A
(en)
|
2020-09-10 |
2023-05-01 |
Genmab As |
A bispecific antibody against CD3 and CD20 in combination therapy for the treatment of diffuse large B-cell lymphoma
|